BM8 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Biomarin Pharmaceutical Inc

Watchlist Manager

Watchlist

Price: 50.68 EUR Market Closed

Market Cap: €9.3B

B	Biomarin Pharmaceutical Inc XBER:BM8	US
	Colliers International Group Inc TSX:CIGI	CA
	PCI- PAL PLC LSE:PCIP	UK
I	Isetan Mitsukoshi Holdings Ltd DUS:4HP	JP
	Nanofilm Technologies International Ltd SGX:MZH	SG
M	MSC Industrial Direct Co Inc F:98M	US
C	Canadian Imperial Bank of Commerce XBER:CAI	CA
	Symbotic Inc NASDAQ:SYM	US
D	DXC Technology Co SWB:2XT	US
	Certara Inc NASDAQ:CERT	US
E	eBay Inc XMUN:EBA	US
U	United Rentals Inc SWB:UR3	US

Profitability Summary

Biomarin Pharmaceutical Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

81%

Strong 3Y Average Gross Margin

79%

Gross Margin is Increasing

77% > 81%

Healthy Operating Margin

27%

Sustainable 3Y Average Operating Margin

15%

Operating Margin is Increasing

3% > 27%

Healthy Net Margin

11%

Sustainable 3Y Average Net Margin

11%

Net Margin is Increasing

3% > 11%

Exceptional Free Cash Flow Margin

22%

Strong 3Y Average Free Cash Flow Margin

12%

Free Cash Flow Margin is Increasing

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.